Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options on May 21, 2026, for thirteen new non-executive employees, covering an aggregate of 93,340 shares of common stock.

Rhea-AI Summary

Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options on May 21, 2026, for thirteen new non-executive employees, covering an aggregate of 93,340 shares of common stock.

The options, granted under the 2021 Inducement Plan, have a $3.70 exercise price and vest over three years with time-based milestones.

Argus May 26 session

-0.24% close to close Open Argus

Details

News Market Reaction – IOVA

In the May 26 session, IOVA declined 0.24%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines routine inducement stock options for new hires, covering 93,340 shares at...

Analysis

This announcement outlines routine inducement stock options for new hires, covering 93,340 shares at an exercise price of $3.70, vesting over three years with an initial one‑third tranche followed by eight quarterly installments. It continues a series of similar grants under the 2021 Inducement Plan. Investors may watch how cumulative equity awards interact with existing authorization proposals and overall hiring and growth plans.

Key Figures

Inducement option shares: 93,340 shares Number of employees: 13 employees Exercise price: $3.70 per share +3 more

Inducement option shares

93,340 shares

Aggregate stock options granted to thirteen new non-executive employees on May 21, 2026

Number of employees

13 employees

New non-executive hires receiving inducement stock options

Exercise price

$3.70 per share

Exercise price equal to closing price on the May 21, 2026 Date of Grant

Vesting period

3 years

Stock options vest over three years, subject to continued employment

Initial vesting

One-third of shares

Vests on first anniversary of each employee’s start date

Subsequent installments

8 quarterly installments

Remaining shares vest over two years after the First Vesting Date

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   Conference appearance

   24h Move

   +4.5%

   Management scheduled for Jefferies healthcare conference fireside chat and webcast.

2. May 07

   Earnings and guidance

   24h Move

   -13.2%

   Q1 2026 revenue growth, guidance, and clinical updates highlighted as positive.

3. Apr 27

   Earnings date set

   24h Move

   -0.3%

   Company scheduled Q1 2026 results call and webcast for investors.

4. Apr 17

   Inducement grants

   24h Move

   -2.1%

   Inducement options for 135,470 shares granted to new non-executive employees.

5. Mar 20

   Inducement grants

   24h Move

   -1.6%

   Inducement options for 3,400 shares granted to a new employee.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock options, nasdaq listing rule 5635(c)(4), exercise price

3 terms

inducement stock options financial

"approved the grant of inducement stock options covering an aggregate of 93,340 shares"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"Each of the stock options ... has an exercise price of $3.70"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 21, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance’s common stock to thirteen new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $3.70, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did Iovance Biotherapeutics (IOVA) grant on May 21, 2026?

Iovance granted inducement stock options for 93,340 shares of common stock to thirteen new non-executive employees. According to Iovance, these options were issued under its Amended and Restated 2021 Inducement Plan as employment incentives consistent with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Iovance (IOVA) inducement stock options?

The exercise price of the new Iovance inducement stock options is $3.70 per share. According to Iovance, this price equals the closing price of Iovance common stock on May 21, 2026, the official grant date for these options to new non-executive employees.

How do the Iovance (IOVA) inducement stock options vest for new employees?

The Iovance inducement stock options vest over three years, with time-based milestones. According to Iovance, one-third vests on the first anniversary of each employee’s start date, and the remaining two-thirds vest in eight quarterly installments over the following two years, subject to continued employment.

How many employees received Iovance Biotherapeutics (IOVA) inducement stock options in May 2026?

Thirteen new non-executive employees received inducement stock options from Iovance in May 2026. According to Iovance, these options collectively cover 93,340 shares of common stock and were granted under the company’s Amended and Restated 2021 Inducement Plan as part of hiring incentives.

Under which plan were the May 2026 Iovance (IOVA) inducement stock options granted?

The May 2026 Iovance inducement stock options were granted under the Amended and Restated 2021 Inducement Plan. According to Iovance, this plan allows its compensation committee to issue equity awards to new employees in compliance with Nasdaq Listing Rule 5635(c)(4).

What employment conditions apply to the vesting of Iovance (IOVA) inducement stock options?

Vesting of Iovance inducement stock options is conditioned on continued employment through each vesting date. According to Iovance, options vest one-third at the first anniversary of employment and the remaining shares in eight quarterly installments over the next two years.